Form 4: Praxis Precision Medicines Executive Sells Shares to Cover Tax Obligations

Lauren Mastrocola, Principal Accounting Officer at Praxis Precision Medicines, sold 35 shares to cover tax obligations related to vesting restricted share units.

Summary

• Lauren Mastrocola, the Principal Accounting Officer of Praxis Precision Medicines, sold 35 shares of common stock on January 7, 2025.
• The sale was executed at a price of $77.52 per share.
• This transaction was to cover tax withholding obligations related to the vesting of previously reported restricted share units.
• Following the transaction, Ms. Mastrocola directly owns 5,871.656 shares of Praxis Precision Medicines.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no significant positive or negative implications for the company's performance or outlook.

Industry Context

This is a routine transaction for executives who receive equity compensation. It is common for shares to be sold to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• Many companies use restricted stock units as part of their compensation packages, and the vesting of these units often triggers tax liabilities.
• Similar transactions are regularly reported by executives at comparable companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Praxis Precision Medicines, insider trading, Form 4, share sale, tax obligations, restricted share units, equity compensation, executive transaction